Head-To-Head Contrast: CareDx (CDNA) & Its Competitors

CareDx (NASDAQ: CDNA) is one of 21 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its peers? We will compare CareDx to related businesses based on the strength of its risk, valuation, profitability, institutional ownership, earnings, dividends and analyst recommendations.

Earnings & Valuation

How to Become a New Pot Stock Millionaire

This table compares CareDx and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
CareDx $48.32 million -$55.46 million -11.26
CareDx Competitors $1.13 billion $76.65 million 204.97

CareDx’s peers have higher revenue and earnings than CareDx. CareDx is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for CareDx and its peers, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CareDx 0 0 4 0 3.00
CareDx Competitors 107 450 529 17 2.41

CareDx presently has a consensus price target of $8.88, suggesting a potential upside of 2.36%. As a group, “Medical laboratories” companies have a potential upside of 17.84%. Given CareDx’s peers higher possible upside, analysts clearly believe CareDx has less favorable growth aspects than its peers.

Risk & Volatility

CareDx has a beta of 0.35, indicating that its share price is 65% less volatile than the S&P 500. Comparatively, CareDx’s peers have a beta of 1.23, indicating that their average share price is 23% more volatile than the S&P 500.

Profitability

This table compares CareDx and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CareDx -114.79% -349.65% -22.88%
CareDx Competitors -118.65% -181.74% -42.76%

Insider & Institutional Ownership

51.5% of CareDx shares are held by institutional investors. Comparatively, 50.4% of shares of all “Medical laboratories” companies are held by institutional investors. 5.4% of CareDx shares are held by company insiders. Comparatively, 18.5% of shares of all “Medical laboratories” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

CareDx peers beat CareDx on 7 of the 12 factors compared.

About CareDx

CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company’s commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

$1.35 EPS Expected for Darden Restaurants  This Quarter
$1.35 EPS Expected for Darden Restaurants This Quarter
BumbaCoin Reaches Market Cap of $124,516.00
BumbaCoin Reaches Market Cap of $124,516.00
AICHAIN  Reaches 1-Day Volume of $34,278.00
AICHAIN Reaches 1-Day Volume of $34,278.00
JobsCoin  Trading Down 37.7% Over Last Week
JobsCoin Trading Down 37.7% Over Last Week
$2.56 Billion in Sales Expected for Discover Financial Services  This Quarter
$2.56 Billion in Sales Expected for Discover Financial Services This Quarter
Zacks: Analysts Anticipate Dover Co.  to Post $1.15 Earnings Per Share
Zacks: Analysts Anticipate Dover Co. to Post $1.15 Earnings Per Share


Leave a Reply

© 2006-2018 Ticker Report. Google+.